<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631484</url>
  </required_header>
  <id_info>
    <org_study_id>CTF-III-CCT-2019</org_study_id>
    <nct_id>NCT04631484</nct_id>
  </id_info>
  <brief_title>International Trial of Efficacy of Cytoflavin in Head Trauma</brief_title>
  <acronym>MITRA</acronym>
  <official_title>International, Multicenter, Randomized, Single Blind, Placebo-controlled Study of Efficacy and Safety of CITOFLAVIN® in the Acute Period of Head Injury in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POLYSAN Scientific &amp; Technological Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POLYSAN Scientific &amp; Technological Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will access the efficacy and safety of treatment with CITOFLAVIN® in patients with&#xD;
      non-penetrating moderately severe traumatic brain injury (TBI). The study recruits patients&#xD;
      18-60 years with TBI, corresponding to the clinical diagnosis of brain contusion, with GCS&#xD;
      score 9 -14 at the time of inclusion , with the estimated time of initiation of therapy&#xD;
      within 24 hours from the estimated or established time of trauma, with post-traumatic&#xD;
      amnesia, confusion or disorientation and absence of indications for neurosurgery or other&#xD;
      surgical intervention under general anesthesia.&#xD;
&#xD;
      Cytoflavin® (Inosine + Nicotinamide + Riboflavin + Succinic Acid) is a combination drug,&#xD;
      which improves cerebral blood flow, activates metabolic processes in the central nervous&#xD;
      system, restores impaired consciousness, promotes regression of neurological symptoms and&#xD;
      improvement of cognitive functions of the brain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">December 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>International, multicenter, randomized, single blind, third party (outcome assessor) blinding</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participant, Outcomes Assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Galveston Orientation and Amnesia scale</measure>
    <time_frame>7 days</time_frame>
    <description>The proportion of patients with regression of post-traumatic amnesia by day 7 of treatment, defined as having a Galveston score of &gt;75 points on 3 consecutive days, up to and including day 7 of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Scale</measure>
    <time_frame>14 days</time_frame>
    <description>Daily assessment by GCS for the period up to 14 days of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome scale - Extended (GOS-E)</measure>
    <time_frame>90 days</time_frame>
    <description>Assessment by GOS-E after 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Head Trauma,Closed</condition>
  <arm_group>
    <arm_group_label>Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive treatment with the study drug, 20 ml twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days;patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 20 ml placebo (0.9% sodium chloride solution) twice a day IV, dissolved in 200 ml of 0.9% NS, for 10 days; patients will stay in the hospital for the the entire period of therapy. Observation of patients and assessment of the main parameters of the efficacy and safety will continue for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)</intervention_name>
    <description>20 ml (2 ampoules, 10 ml each) dissolved in 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days.</description>
    <arm_group_label>Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 ml of 0.9% sodium chloride (2 ampoules of 10 ml each), added to 200 ml of 0.9% sodium chloride, intravenously 2 times a day with an interval of 12 ± 2 hours, for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18-60 (inclusive).&#xD;
&#xD;
          2. Clinical diagnosis of TBI, cerebral contusion of moderate severity without&#xD;
             compression.&#xD;
&#xD;
          3. The written consent of the legal representative or the decision of the council to&#xD;
             include the patient in the study.&#xD;
&#xD;
          4. Possibility of a full assessment of eye opening, speech and motor response by GCS.&#xD;
&#xD;
          5. GCS at the time of inclusion 9 - 14 (inclusive).&#xD;
&#xD;
          6. Time of initiation of study drug therapy within 24 hours after the estimated or&#xD;
             determined time of injury.&#xD;
&#xD;
          7. The presence of post-traumatic amnesia, confusion and disorientation.&#xD;
&#xD;
          8. Absence of indications for neurosurgery or other surgical intervention under general&#xD;
             anesthesia.&#xD;
&#xD;
          9. Normal brain CT scan, or the presence of subarachnoid hemorrhage and / or contusion&#xD;
             foci of I-III types according to Kornienko and / or limited or diffuse cerebral edema.&#xD;
&#xD;
         10. The expected duration of hospital stay &gt;= 10 days.&#xD;
&#xD;
         11. Absence of a disabling neurological or mental illness, information about the patient's&#xD;
             disability prior to injury.&#xD;
&#xD;
         12. Possibility to perform all procedures stipulated by the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The need to use the therapy prohibited by the study protocol.&#xD;
&#xD;
          2. Concomitant injury, except for cases of damage to the skeleton, soft tissues, internal&#xD;
             organs, which do not require (1) surgical intervention under general anesthesia, and&#xD;
             (2) are not an independent indication for hospital treatment.&#xD;
&#xD;
          3. Past / planned surgical intervention for the current episode of trauma under general&#xD;
             anesthesia.&#xD;
&#xD;
          4. Penetrating open TBI.&#xD;
&#xD;
          5. Presence of the following lesions on the results of computed tomography (CT) of the&#xD;
             brain performed prior to the patient's randomization:&#xD;
&#xD;
               1. epidural hematoma or subdural hematoma;&#xD;
&#xD;
               2. evidence of a previous head injury based on CT results;&#xD;
&#xD;
               3. type IV contusion foci according to Kornienko's classification.&#xD;
&#xD;
          6. Presence of any of the following risk factors for secondary brain injury at any time&#xD;
             after TBI: hypoxia (SpO2 &lt;90% based on pulse oximetry results); hypotension (systolic&#xD;
             blood pressure &lt;90 mm Hg) or shock;hypothermia (body temperature &lt;35 ° C); clinical&#xD;
             signs of respiratory failure, the need for mechanical ventilation.&#xD;
&#xD;
          7. Drug addiction.&#xD;
&#xD;
          8. Alcohol in saliva &gt;=2 ‰ or a previous diagnosis of alcohol dependence.&#xD;
&#xD;
          9. Depression of consciousness, presumably resulting from other reasons (for example,&#xD;
             alcohol, drugs, drugs, poisonous substances).&#xD;
&#xD;
         10. The presence of aphasia due to focal brain damage, which prevents communication with&#xD;
             the researcher.&#xD;
&#xD;
         11. Status epilepticus at the time of admission to the hospital or condition after an&#xD;
             epileptic seizure.&#xD;
&#xD;
         12. Pregnant and lactating women.&#xD;
&#xD;
         13. Availability of information about concomitant chronic disease in the stage of&#xD;
             decompensation.&#xD;
&#xD;
         14. Intolerance to the components of CYTOFLAVIN®, anamnestic data on drug allergy to&#xD;
             succinic acid, riboflavin, inosine, or nicotinamide.&#xD;
&#xD;
         15. Severe renal or heart failure requiring restriction of the volume of injected fluid.&#xD;
&#xD;
         16. The presence of a condition or disease that, in the opinion of the investigator,&#xD;
             jeopardizes the patient's safety if the patient participates in the study, or may&#xD;
             interfere with the performance of examination procedures, an objective assessment of&#xD;
             the patient's condition, or distort the assessment of the outcome of TBI.&#xD;
&#xD;
         17. Participation in any clinical study less than 3 months before the start of the study.&#xD;
&#xD;
         18. Patients who are employees of the research center and their families.&#xD;
&#xD;
         19. Language barrier.&#xD;
&#xD;
         20. Availability of information that the patient is a stateless person or a citizen of&#xD;
             another state&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aleksey L Kovalenko, Doc Biol Sci</last_name>
    <phone>+78127108225</phone>
    <phone_ext>212</phone_ext>
    <email>science@polysan.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana Kharitonova, MD, PhD</last_name>
    <email>t_haritonova@polysan.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City Hospital №40 of the Kurortny District</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina S Agafyina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anton S. Povzun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital of the Holy Martyr Elizabeth</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>closed head injury</keyword>
  <keyword>brain concussion</keyword>
  <keyword>traumatic brain injury</keyword>
  <keyword>TBI</keyword>
  <keyword>Craniocerebral Trauma</keyword>
  <keyword>posttraumatic amnesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Head Injuries, Closed</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

